Aerosolized formulations for pulmonary administration

Respiratory infections caused by multidrug-resistant pathogens are particularly challenging to manage and are associated with substantial morbidity and mortality. In a scenario of escalating antimicrobial resistance, these infections represent an increasingly important global healthcare concern. Conventionally, they are treated via systemic administration but only a limited proportion of the administered antibiotic reaches pulmonary tissues, which can diminish efficacy and requires higher doses to achieve therapeutic effects. 

Excess circulating drug may then distribute to non-target organs, increasing the risk of adverse effects, including gastrointestinal disturbances and ototoxicity. In contrast, inhalation offers important advantages related to the delivery of the drug directly to the lungs, i.e., the primary site of infection. This targeted deposition can achieve higher local concentrations and sustain antibacterial activity for longer periods while requiring lower total doses, thereby reducing systemic exposure, limiting side effects, and improving patients’ quality of life relative to other routes of administration. However, it is evident that new formulations are required to enable efficient, direct delivery to the lungs. Wet nebulization remains the most widely used approach for pulmonary administration of antibiotics; however, it has several limitations, including relatively complex administration procedures, a higher susceptibility to reinfection, reduced drug stability, and lower patient acceptance when compared with dry powder inhalers.

Description

This Cutting-Edge Biomedical Solution (CEBS) represents a global solution for the development and full characterization of aerosolized formulations aimed at pulmonary administration, including the development of novel drug encapsulating biocompatible materials and even novel self-assembly of drugs for direct aerosolization. It also offers the possibility of exploring and adjusting the parameters required for the correct development of a successful formulation of the final product in an aerosolized form. A precise control on particle size and agglomeration is key to achieve delivery to the distal areas of the lung.

More info: https://www.nanbiosis.es/aerosols-for-pulmonary-administration/